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One of the biggest challenges that the healthcare industry faces today is the 
accentuated growth of operating costs. Fighting this growth cannot be done 
without taking into account the quality of services provided in healthcare units. 
Improving cost efficiency through the implementation of more efficient and 
effective purchasing strategies is one way to reduce costs.  
 
The first objective of this dissertation was to understand the link between supply 
chain cost efficiency and quality in healthcare organizations taking the 
Portuguese Healthcare System as an example. The second objective was to assess 
the potential of increasing quality through cost reduction that the creation of a 
Group Purchasing Organization could have in the Portuguese Healthcare System. 
 
An analysis of the evolution of costs between 2011 and 2017 was made with 
secondary data from financial and operational reports made available by the 
Portuguese Healthcare System. It was found that positive variations in cost 
efficiency can generate positive variations in quality and therefore new 
purchasing strategies should be addressed to strengthen this linkage. Regarding 
the implementation of a Group Purchasing Organization, an analysis of the 
current purchasing model and its capacity to save financial resources was 
undertaken. It was concluded that the creation of a Group Purchasing 
Organization could increase quality due to its potential to save money and 
















Titulo: Melhorar a eficiência de custos na cadeia de abastecimento 
dos hospitais para aumentar a qualidade: avaliação da criação duma 
Organização de Compras de Grupo no Serviço Nacional de Saúde 
Português.  
 
Autor: Eduardo Villax. 
 
Um dos maiores desafios que o setor da saúde enfrenta atualmente é o 
crescimento acentuado dos custos operacionais. Tentar inverter esse 
crescimento não pode ser feito sem ter em conta a qualidade dos serviços 
prestados nas unidades de saúde. Melhorar a eficiência de custos através da 
implementação de estratégias de compras mais eficientes e eficazes é uma das 
formas de reduzir custos. 
 
O primeiro objetivo desta dissertação foi compreender a relação entre eficiência 
de custos na cadeia de abastecimento e qualidade nas organizações de saúde, 
tendo como exemplo o Serviço Nacional de Saúde Português. O segundo objetivo 
foi avaliar o potencial de aumento da qualidade através da redução de custos que 
a criação de uma Organização de Compras de Grupo (ou central de compras) 
poderia ter no Serviço Nacional de Saúde Português. 
 
Uma análise da evolução dos custos entre 2011 e 2017 foi feita com dados 
secundários de relatórios financeiros e operacionais disponibilizados pelo 
Serviço Nacional de Saúde Português. Verificou-se que variações positivas na 
eficiência de custos podem gerar variações positivas na qualidade e, portanto, 
novas estratégias de compra devem ser abordadas para fortalecer essa ligação. 
Em relação à implementação de uma Organização de Compras de Grupo, foi 
realizada uma análise do atual modelo de compras e sua capacidade de poupar 
recursos financeiros. Concluiu-se que a criação de uma Organização de Compras 
de Grupo poderia aumentar a qualidade devido ao seu potencial para poupar 
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1. Problem statement. 
 
 
This thesis aims at understanding the link between supply chain cost 
efficiency and quality in healthcare organizations, and assess the 
potential of the creation of a Group Purchasing Organization in the 
Portuguese Health System to increase quality through cost reduction. 
 
 
2. Research Questions. 
 
1: What is the link between supply chain cost efficiency and quality in 
healthcare? 
 
2: What is the potential of the creation of Group Purchasing 
Organization to increase quality through cost reduction in the 




3. Topic presentation. 
 
Quality in healthcare organizations is very important to ensure customer’s safety 
and satisfaction. Monitoring several performance indicators through the 
collection of massive amounts of data and the continuous improvement of these 
indicators is fundamental to keep an effective and trustful quality system.  
Quality in healthcare organizations is mostly defined as the aspect that has to 
deal with care levels compliance to sector regulations, attention and respect of 
commitments to users by the organizations (Kwon et al., 2016). This definition 
aims at providing the best quality healthcare services to the end user. One way of 
improving quality is by increasing the efficiency of healthcare organizations 
supply chain that will boost cost efficiency and resource availability. Boosting 
cost efficiency will allow to release financial resources to invest in other areas. 
Regarding resource availability, the improvements can tackle problems related 
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with equipment and supplies such as missing, malfunctioning and calling for 
cumbersome processes to acquire (Mendonça, 2017).  
Supply chain inefficiencies are very costly and even if this theme has recently 
attracted attention by scholars, researchers and government officials, the 
Pricewaterhouse Health Research Institute reported that in 2008, $1.2 trillion 
out of $2.2 trillion in healthcare spends is a waste of money (Kavilanz, 2009). 
Considering that the United States is the world’s leading economic power 
(Investopedia, 2017), there is surely room for improvement in these numbers. 
For many years healthcare supply chains were considered different from 
commercial supply chains (e.g. manufacturing companies, global service 
providers) and as consequence we have today an important gap between 
healthcare and commercial supply chains (Kwon et al., 2016). This gap is mainly 
explained by the fact that commercial supply chains evolved more and faster due 
to the adoption of innovative and powerful supply chain tools such as Vendor 
Management Inventory (VMI) or Collaborative Planning Forecast Replenishment 
(CPFR). Some of these tools were also introduced in healthcare supply chains but 
in the wrong timings: late and slowly.  
Cooperative purchasing is a procedure that consists in the cooperation of two or 
more organizations in the purchasing process, usually in the same industry, by 
sharing purchasing volumes, market information and demand resources (Burns 
& Lee, 2008; Schotanus & Telgen, 2007; Bakker et al., 2008). This cooperation 
results in the creation of a Group Purchasing Organization (GPO)  that typically 
increases integration and purchasing centralisation (Monczka et al., 2010). This 
technique is widely spread across the world: over 70% of healthcare spends are 
managed through GPOs (Kwon et al., 2016). But in Portugal and particularly in 
the National Healthcare System, there has been very little or unsuccessful 
adoption (Rego et al., 2013).  
Considering the heavy cost structure of healthcare supply chains and the 
importance of cost containment without compromising quality, we will address 
the two research questions presented above in the context of the Portuguese 
National Healthcare System. The objective will be to understand what is the link 
between costs incurred by healthcare organizations and the quality of services 
provided. The second objective of this study will be to understand the potential 
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that the creation of a Group Purchasing Organization in the Portuguese 
Healthcare System would have to increase quality through cost reduction.  
 
The managerial relevance of this topic stands in the need of continuously 
improve healthcare operations and particularly those that are more cost 
intensive: supply costs accounted for 30% to 40% of total operational costs of 
the Portuguese National Health System in 2009 (INFARMED, 2012). Thus, 
introducing collaborative purchasing in healthcare supply chains through the 
creation of GPOs has proven its effectiveness in containing rising costs by 
reducing product prices in two ways: through pooled purchasing leverage of 
hospitals buying products on nationwide contracts and through the 
establishment of price ceilings beneath which hospitals negotiate on their own 
(Burns et al., 2008; Monczka et al., 2010). 
The scope of this work will be the whole Portuguese National Health System and 
particularly the supply chain of the healthcare units that compose it. We intend 
to analyse supply chain operations starting in the demand points that lead to 
order placements and negotiation with suppliers until the entry of material in 
the warehouse. This may also include inventory management inside the 
warehouse. We will be treating both the supply of pharmaceuticals and medical-
surgery materials (consumables), and the associated services needed to provid 
care. 
In the outline of this dissertation, there will be five main chapters. After this 
introductive chapter, a literature review will be conducted on relevant subjects 
for our topic such as supply chain management in the healthcare industry, 
quality management in healthcare and collaborative purchasing. This chapter 
will also include an overview of the Portuguese National Healthcare System. In 
chapter 3, there will be a data collection process in order to get answers to our 
research questions and to draw conclusions of these. The analysis of the results 
obtained will be provided in chapter 4. The last chapter will focus on the main 
conclusions of our research, give insights about the limitations found during the 









Considering our first objective of understanding the link between supply chain 
cost efficiency and quality in healthcare organizations, we will make use of 
secondary data such as the financial records of hospitals and operational reports. 
This data should be easily accessible because it is provided by the Portuguese 
government and it is for public access.   
Regarding the implementation of a Group Purchasing Organization and its effect 
on quality, secondary data will be collected in order to understand the current 
operation of the Portuguese Health System in terms of purchasing activities and 
its performance.  
A deductive approach will be used through this study to compare the data 
collected within different period and to draw conclusions that answer to the 


























1. Supply Chain Management 
1.1 Global Supply Chain Management (costs, types of waste) 
 
The Institute for Supply Management defines supply chain management as “the 
identification, acquisition, access, positioning, management of resources and 
related capabilities the organization needs or potentially needs in the attainment 
of strategic objectives. Looking at the narrower and more customer-centric 
definition, supply chain management is the sum of total operations performed 
and the parties that execute them, direct or indirectly, to produce and deliver a 
customer request (Kros & Brown, 2013).  
All the activities completed along the supply chain have direct or indirect costs 
associated that have an important impact in a company’s performance. Above, 
we briefly resume the different costs that apply both for companies that deliver 
goods and companies that deliver services. 
 
The acquisition cost of a product is the price paid by the company for a certain 
item. This price can be subject to a discount of quantity, as we will see in part III 
of this chapter.  
 
Transport is responsible for the movement of physical goods between points in 
the supply chain. Shipping costs, incurred with the transportation of goods 
between the producer and the company, account for the majority of 
transportation costs. The importance of these costs is highly affected by the 
transportation type chosen: rail, road, water, air or pipeline (Waters, 2003) 
 
After transportation, there is need to keep the inventory in a safe place and 
storage costs are incurred. These are all the costs associated to stock that is stuck 
in the warehouse. There are fixed costs such as facility leases, insurance and 
owned equipment. Variable costs are those associated with travel distances, 
touches and paper (handling costs) (Minghini 2016). This is where much can be 
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done to boost efficiency in the warehouse by optimizing routes and reducing the 
number of times that an employee touches the same pallet, and by replacing 
paper by electronic devices. 
According to Ohno (1988), waste refers to all elements of production or service 
provision that only increase costs without adding value, that is, the activities that 
do not add value from the customer perspective but are performed within the 
production process. Suzaki recognized 7 sources of waste that should be 
eliminated (Askin & Goldberg, 2002): waste from overproduction, waste of 
motion, transportation waste, processing waste, wasted time (queuing), 
defective products and excess inventory. Reducing waste in the supply chain 
reduces costs and employees’ workload while improving global efficiency. Even 
in industries with very complex process specifications and compliances rules 
such as healthcare, there is room for waste reduction. 
 
 
1.2 Healthcare supply operations. 
 
“The operations and supply function in hospitals has historically been viewed as 
having a limited scope, many times falling under the term materials 
management” (Kros and Brown, 2013). This reality has been changing over the 
last 15 years and an increasing number of hospitals have been implementing 
supply chain tools to modernize their supply systems. Nevertheless, there is still 
room for improvement. For example, this sector is operating heavily Less Than 
Truckload (LTL) in the domain of transports and distribution; more than 50% of 
the operations are performed LTL which increase costs and the probability of 
damaging materials. Warehouse utilization rates are as low as 60 to 70 % of the 
capacity and stock rotation rate is only 2 times against for example 44 times in 
consumer electronics (Dooner, 2014). Regarding the logistic cost, the healthcare 
industry is one of the biggest consumers in this field with the latter accounting 
for 38% of the total expense while the same is 5% for the retail industry and 2% 
for the electronic industry (Johnson, 2015). The logistic cost is not the only big 
challenge in healthcare supply chains as this industry must also follow very strict 
rules when transporting pharmaceutical material.  
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Healthcare supply chains face rigorous regulatory requirements in the 
distribution process of pharmaceuticals to ensure the quality of these from the 
manufacturer until reaching the warehouse in the hospital. All the companies 
dealing with pharmaceutical products must follow the Good Distribution 
Practices. 
That is why healthcare organizations must take into account all stakeholders 
taking part in the process until the products enter the warehouse: 
manufacturers, wholesalers, warehouses, freight consolidators, freight 
forwarders and brokers (Schmitt, 2014). Quality and compliance issues may 
arise at any point of the production and distribution chain and particularly from 
third party providers. Therefore healthcare organizations should audit and 
control all their business partners that intervene in the pharmaceuticals 
purchasing process (EMA, 2013).  
In the European continent, the Good Distribution Practice guidelines are 
provided by the European Commission with the document  “Good distribution 
practice of medicinal products for human use” (Nov. 5, 2013). This document 
highlights the importance of complying with quality standards in the distribution 
of healthcare products and gives insights in key areas such as storage, 
management of outsourced activities, hygiene and transportation of products 
requiring special conditions (e.g. temperature controlled transport). Besides 
keeping quality standards, the Good Distribution Practice guidelines aims at 
reducing and teach how to deal with falsified medicinal products (MHRA, 2013). 
Due to these specifications and other factors, healthcare supply chains were 










1.3 Commercial supply chains VS healthcare supply chains 
 
Commercial supply chains refer to manufacturing, retail or global services 
providers companies and healthcare supply chains are those that supply 
hospitals. Commercial supply chains are said to be years ahead of healthcare 
supply chains. This gap has roots in the perspective that was built around 
healthcare supply chains giving it limited scope and equating it to materials 
management (Kros & Brown, 2013). Another major reason to justify this gap is 
linked with a complex and dynamic internal and external environment that 
characterizes hospitals. The complex technology used, the distinctive 
characteristics of health service operations and the presence of multiples 
stakeholders makes it hard to implement supply chain practices commonly used 
in industrial settings (De Vries & Huijsman, 2011). As a consequence, we observe 
many supply chain tools that have been implemented and deeply developed in 
industrial supply chains such as Supplier Relationship Management (SRM),  
standardisation or the lean concept that have only been introduced recently in 





2. Quality Management in Healthcare 
2.1 Definition and levels of quality 
 
“Many experts have attempted to define quality. While definitions vary, there are 
three standard levels of quality that are accepted today” (Dunn, 2010). The first 
is conformance quality and it is the most rudimentary level of quality. It means 
ensuring to the customer the minimum quality standards defined by the 
organization. The second level is requirements quality where the company’s 
manager is responsible to meet the customer’s requirements and expectations 
showing that he is running a good organization. The highest level is quality of 
kind: the service or product provided by the company beats customer’s 
expectations or delights the customer.  
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In healthcare, the focus is in service quality that is linked to the previous 
definition of quality with some nuances. We can classify health service quality in 
3 different dimensions: 
- Technical and professional quality: it is based on technical accuracy and 
correct practises. Consistent medical diagnoses, compliance with industry 
specifications, and proper tests are all examples of technical and 
professional quality. Competence and knowledge of medical staff, 
including the surgeon’s operating skills and the nurses’ ease and 
familiarity with drug administration, is also considered technical quality. 
(Kros & Brown, 2013). 
- Quality of management: “the ability to use the available resources 
efficiently through an organizational system that limits waste, and work 
under constraints and directives imposed” (Giannini, 2015). 
- Quality perceived by the use: difference between customers’ expectations 
and customer’s perceptions that allows the healthcare provider to 




2.2 Managing quality in healthcare. 
2.2.1 Quality control 
 
In order to assess and manage quality in a healthcare unit, data must be 
constantly collected, monitored and analysed. The data collected will allow using 
quality control tools with the primary objective of achieving quality of kind. 
Kauro Ishikawa developed 7 quality control tools that enable healthcare 
managers to address, analyse and solve the vast majority of quality issues. The 7 
quality control tools are: cause- and-effect diagrams, check sheets, control charts, 
flowcharts, histograms, Pareto diagrams and scatter diagrams.  These tools help 
managers to control quality of the day-to-day operations of healthcare units and 
to spot problems that need to be solved. To assure that an adequate level of 
quality is achieved, managers may also use the Deming Management Method. 
Developed by the latest, it consists in a set of 14 points of behavioural and 
organizational practises that aim at keeping high quality standards. Deming said 
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that a manager should always appreciate a system correctly, have good 
knowledge of variation, understand the theories of knowledge and have 
sensitivity for the concepts of human nature.  
Managing quality control and continuously introducing ways to improve quality 
will have an impact in key financial ratios and metrics healthcare related that 
will be our main focus in which regards quality management.  
 
2.2.2 Relationship between costs and quality. 
 
Given that costs are present in the majority of the key healthcare financial ratios 
that we will present later, it is important to introduce and define the theoretical 
relationship between quality and costs. The theoretical relationship between 
quality of care and healthcare costs has been represented by graphs like the one 
in figure A (Bodenheimer and Grumbach, 2009; Donabedian, Wheeler, and 
Wyszewianski, 1982). 
As we can see, the curve is S-shaped. In the beginning, increasing costs will only 
increase quality residually. As costs continue to increase, quality will start to 
increase exponentially until reaching a final stage. At this point, each increase in 
cost will have a meaningless impact in quality; the growth in quality is not worth 





Figure A: Theoretical relationship between quality and costs. (Joshi et al., 2014)  
 
Donabedian (2003) summarized the relationship between quality and costs by 
defining 3 rules.  
Firstly, to achieve any level of quality, financial resources will have to be spent: 
quality costs money. 
Secondly, even though higher costs are usually associated with higher quality, 
every unit of cost added will not necessarily increase the overall quality as 
showed by points A and B in figure B: money does not necessarily buy quality.  
Thirdly, as seen in figure A, at some point, continuing investing financial 
resources will only bring small enhancements in quality and therefore some 
improvements in quality are not worth the added cost. “In this kind of situation, 
some would argue that the large increase in costs is not justified, given the 
disproportionately small improvement in quality” (Joshi et al., 2014). 






Figure B: Money does not necessarily buy quality. (Joshi et al., 2014). 
 
With the relationship between costs and quality in healthcare defined and the 
concept of quality control introduced, the measurement of quality is the next 
subject to be addressed. 
 
2.2.3 Financial ratios and metrics. 
 
Quality supporters such as Deming (1982) and Harteloh (2004) argued that 
quality was a fundamental driver of productivity and performance. In Figure C, 
we introduce some key healthcare financial ratios that will help us later to 
understand the link between quality and financial performance in healthcare 








Liquidity ratios Profitability Ratios 
Inventory Turnover Current ratio Operating margin 
Days in patient accounts 
receivable 
Quick ratio Return on assets 
Case mix index Average pay period 
Supply expense to net 
patient revenue 
Working capital 
Supply expense to 
operating revenue 
Days of working capital 
Supply expense to 
adjusted patient days 
Supply expense to 
adjusted charges 
Figure C: Key healthcare financial ratios (Kros and Brown, 2013). 
 
Given our focus in supply chain operations, we will only develop further asset 
management ratios and profitability ratios that are among the most important in 
this field.   
 
• Inventory Turnover Ratio: Cost of Goods Sold / Average Inventory 
Cost of goods sold is the cost incurred with supplies (e.g. pharmaceuticals or 
surgery material) to provide care to patients. This ratio tells us how many times 
inventory is out of stock and restocked or turned over during the year.  
 
• Supply Expense to Net Patient Revenue: Supply expense / Net 
Patient Revenue.  
Supply expense is the same as the cost of goods sold, explained in the previous 
ratio. The net patient revenue is sum of the net patient service revenue and the 
premium revenue. This ratio is very helpful when analysing supply expenses 
performance on a period-over-period time frame. If the ratio increases over time, 
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it may indicate that that changes in supply management behaviour are occurring 
such as consumption, prices or supplier without any changes in patient revenue. 
 
• Supply Expense to Total Operating Revenue = Supply Expense / 
Total Operating Revenue 
The only difference in the calculation between this ratio and the supply expense 
to net patient revenues is that all the revenues are taken into account for latter 
one and not only the net patient revenue. It measures the relative intensity of 
supply utilization in support of patient care and day-to-day operations. 
According to the healthcare industry standards, companies that are performing 
better have a ratio between 13 and 14 per cent.  
 
•  Supply Expense to Adjusted Patient Days = Supply Expense / 
Adjusted Patient Days. 
Adjusted patient days is the formula that measures the mix between outpatients 
and inpatients, patients staying less than 24 hours and those staying more than 
24 hours in a healthcare facility.  
Adjusted Patient Days = (Total Gross Revenue / Total Inpatient Revenue) * 
Number of Patient Days 
Number of patient days is the sum of the total number of days spent by each 
patient in the healthcare unit. 
 
• Operating Margin = (Operating Revenue – Operating Costs) / 
Operating Revenue. 
It is the most common ratio for any type of organization. The healthcare industry 
average in 2010 was 3,4 per cent (Carlson and Galloro, 2011). 
 
2.2.4 Performance indicators. 
 
“Performance indicators are a popular mechanism for measuring the quality of 
healthcare to facilitate both quality improvement and systems management” 
(Braithwaite et al., 2017). Besides financial ratios, performance indicators may 
also be used to assess the quality of services provided by healthcare units. The 
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World Health Organization established some indicators in order to compare 
healthcare performance between different countries. The measurement of these 
indicators aims at conferring the level of health provided to the population by a 
health system, understanding to which extent responsiveness to human needs 
are being met and evaluating the health resources productivity (Smith et al., 
2009). There are general indicators that enable to assess the overall health 
status of the population and its evolution over different periods such as the life 
expectancy or avoidable mortality. To monitor more specifics aspects of 
healthcare operations, there are performance indicators such as the readmission 
rate after a patient discharge from hospital (Daras et al., 2017) or the total time 
that a patient waits for a surgery (Waddel, 2008). With the data collected about 
these indicators in healthcare units, it is possible to provide insights about 
operational performance that reflects the level of quality practised.   
 
In this chapter were introduced important quality concepts such as control and 
monitoring of quality, the relationship between costs and quality, and a set of 
tools to measure it. Witch the next chapter comes an overview of the Group 




3. Collaborative purchasing. 
3.1 Definition of GPO. 
 
“A group purchasing organization (GPO) is an entity that utilizes collective 
buying power to obtain significant discounts from vendors, which can be 
suppliers, distributors and manufacturers”. (Yang et al., 2016). Weinstein 
defined a healthcare GPO as an intermediary in the supply chain for 
pharmaceuticals and medical equipment with the hospitals and clinics being 
stakeholders that aim at aggregating purchases and thereby achieving lower 
prices from suppliers (Weinstein, 2006). Two or more companies, usually from 
the same industry, form this entity. In the case of healthcare, an example of a 
GPO would be an entity that negotiates and purchases products for 2 or more 
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hospitals from a set of vendors. That means that one single vendor may be 
supplying more than one hospital.  
The vendor is better off selling through a GPO because it offers possibly higher 
volumes purchased but requires that the vendor pay to the GPO a Contract 
Administration Fee (C.A.F.), a percentage of all revenue contracted through it. 
The companies benefiting from the GPO are better off because they may have 
cost reduction due to increased bargaining power but may have to pay a 
membership fee (Hu et al., 2011).  
 
 
3.2 Advantages and disadvantages of GPOs. 
 
The formation of GPOs may bring lots of advantages to the companies composing 
the group but may also bring disadvantages. From Appendix A that includes the 
main advantages and disadvantages from collaborative purchasing, below we 
resume the more important ones for our study.  
 
At individual member level 
The companies integrating a GPO will mainly benefit from cost reductions (e.g. 
cost, transaction and administrative costs) and savings in human resources, 
given that some purchasing effort will be transferred to the group alongside with 
increased information on supply markets that improves the decision making 
process (Schneller, 2009). Lower responsiveness in emergency situations when 
smaller quantities are needed, less direct contacts with the suppliers and 
standardization are the disadvantages at this level. The only concern at his level 
is the possibility of negotiating a higher price within the GPO than if the price 
was negotiated directly with the supplier (Dimitri et al., 2006).  
 
At group / supply chain level 
Advantages at this level are multiple. Better information and standardisation 
enables a more rationalised choice. The consolidation of purchasing volumes 
enables negotiating better conditions with the suppliers and the reduction of 
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duplicated purchases. With the increase of the number of participants in the 
GPO, increases also the coordination costs (Tella & Virolainen, 2005). 
 
At macro / political level 
In the field of politics, the reduction of overall supply chain costs will 
consequently decrease the amount paid by taxpayers. There is also a positive 
effect in the prevention of corruption in the public sector. Regarding 
disadvantages, innovation can be highly affected as GPOs tend to favour 
suppliers with a wide product range rather than the ones with a single 
innovative product. At the macro level, there is major concern about keeping 
market dynamics given that setting up a GPO increases considerably buyer 
concentration (Blair and Durrance, 2013). 
 
 
3.3 Group Purchasing organizations in Portugal healthcare system. 
 
“It may be argued that the best solution for Portuguese Public Hospitals would 
be the establishment of a national GPO” (Rego et al., 2013). Actually, over the 
past years, there have been many attempts from the health authorities to 
implement and control group purchasing structures. Nevertheless, due to wrong 
timings or wrong approaches, the reported purchases channelled through this 
type of structures were very few. The creation of these organizations has even 
experienced resistance and low acceptation from hospital staff, explained 
primarily by strict compliance rules. The introduction of collaborative 
purchasing organizations in the Portuguese National Healthcare System has 
followed an opposite path to the one proposed by Schotanus and Telgen that 
approaches the commonly observed evolution in this field by different nations. 
According to Definitive Healthcare Data, a U.S. repository of healthcare data, it 
was estimated that already over 90% of the total number of hospitals in the U.S. 
were members of a GPO in 2017. 
The Portuguese Ministry of Health created in 2010 the SPMS – Serviços 
Partilhados do Ministerio da Saude (Ministry of Health Shared Services), a public 
institution owned by the government. This entity’s mission is providing services 
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related to procurement and logistics, financial management, human resources 
and information technology systems to institutions that are part of the National 
Health System such as hospitals (SPMS, 2015). The constitution of the SPMS aims 
to promote efficiency and effectiveness of the National Healthcare System 
associated entities through the attainment of savings when purchasing 
medicines, consumables, medical devices and services linked to field of 
healthcare. The participation of the SPMS in the purchasing processes varies 
according to the purchasing model attributed to each product or service: there is 
the distributed model and the centralized model.  In the distributed model, the 
institution centrally defines the basic conditions for future contracts between 
suppliers and companies that are members of the National Health System 
through the conclusion of framework agreements; the individual purchases are 
then performed decentrally by each healthcare unit. In the centralized model or 
aggregated, the SPMS undertakes the individual purchases on behalf of the 
healthcare units through framework agreements or through other procedures of 
public contracting if there is no agreement in place for the type of good or 
service (SPMS, 2015).  
The total savings amount for the National Health System is defined by the cost 
reduction, incurred by the attainment of better conditions in the purchase of 
goods and services by the institutions that compose it: transactional savings; and 
by the reduction of resources allocated to buying processes that arises from the 
centralization and aggregation of all purchases: procedural savings. The sum of 
these two sources of savings represents the global savings for the National 
Health System.   
The global savings of the National Health System is boosted through: 
- The reduction of transactional expense that arises from the conclusion of 
framework agreements that set up maximum prices for products and 
services and from the centralization and aggregation of purchases that 
enables the increase of bargaining power and consequently more 
competitive prices. 
- The reduction of procedural expenses that arises from the retrenchment 
of costs and workforce effort in the execution of buying procedures under 
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agreements, by the reduction of the number of competing proposals for 
each award and the elimination of costs with tender advertisement.  
 
Since the introduction of the centralized purchases and the intervention of 
the SPME in the buying process, the Portuguese government has taken a big 
advantage and saved large amounts of money. In 2017, the SPME estimates 
that 985 million euros of purchases have been performed centrally enabling 
global savings of 145 million euros (Publico, 2017). The introduction of a 
GPO could boost this number and cover the purchase of a wider range of 


























III.  Methodology and Data Collection. 
 
1. Study Design 
1.1 Contextual overview. 
 
The healthcare industry has faced for long years very high costs and principally 
increasing costs. As an example, the United States saw their healthcare costs rise 
by 933 billion dollars from 1996 to 2013 (Forbes, 2017), making the United 
States the country with the biggest health expenditure per capita. According to 
the OECD, all its members experienced an annual growth in healthcare 
expenditure between 2003 and 2009 and only 3 countries were able to reduce it 
between 2009 and 2016. In the cost structure of healthcare organizations, 
operational costs account for a very important part of the total and Portugal is 
not an exception: the INFARMED estimates that 30% to 40% of the overall costs 
were operational costs in 2012. Therefore, reducing operational costs is an 
important and hardworking task because with it comes another challenge: try to 
increase quality levels or at least keep the current ones. Bearing this in mind, this 
study focused on supply chain costs and its influence in the quality of services 
provided in healthcare organizations. After having established a relation 
between supply chain costs and quality, this study intends to assess the potential 
of increasing quality through cost reduction that the creation of a Group 
purchasing Organization could generate in Portuguese Health System.  
 
 1.2 Scope of the study. 
 
Considering the goals of this study, the two research questions will be addressed 
to the Portuguese Health System, which will facilitate the process. The strong 
linkage of the author to Portugal was also taken into account to make this 
decision. As the Portuguese Health System is owned by the government, there 
are multiple financial, operational and performance reports that are public and 
of easy access; some of these reports are even mandatory for the healthcare 
units to disclose them. The Portuguese Healthcare System is composed by 77 
general hospitals and by 22 specialized hospitals covering all the geographical 
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regions of Portugal (Pordata, 2017). The data for the analysis will be collected 
from all the hospitals with no restriction whenever it is available. 
 
2. Data Collection  
 
The data to undertake this study will be collected from multiple reports that are 
available online and provided by the Portuguese Healthcare System. The study 
will mainly focus in the period between 2011 and 2017, period which has more 
data available and consistent.  Assuming a positivistic philosophy, where all 
previous literature is considered accurate (Collis & Hussey, 2003), conclusions 
will be drawn according to the consulted literature.  
 
2.1  Relation between costs and quality. 
 
 
The first objective of this study is to understand the link between cost efficiency 
and quality in healthcare supply chains. This objective aims at defining the 
relation of money spent on the quality provided to the healthcare consumer: a 
person that seeks to be treated or that seeks for a diagnosis. According to 
Donabedian (2003), one of the major outcomes on quality that may arise from 
the variation of costs incurred by a healthcare unit is that each extra monetary 
unit spent does not necessarily have a positive impact on quality. This leads one 
to another interesting hypotheses: reducing costs may increase quality (Kros & 
Brown, 2013). With the increase in cost efficiency, resources may be allocated to 
other areas in need and therefore increase the overall quality. 
To better understand this relation between costs incurred and quality, secondary 
data from the Portuguese Healthcare System will be collected in order to analyse 
and validate these hypotheses. Considering the information available and the 
goal of seeing the evolution of costs since 2011, data collected about cost 
indicators will mainly be about medicines used in the institutions that compose 
the Portuguese Health System. Regarding quality, the data collected was 
extracted from operational performance reports where trends about quality 
evolution are more easily understandable. As an example, these reports can 
measure the readmission rate to hospital after a patient discharge or the average 
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waiting time for a surgery to be performed. Key financial ratios were not taken 
into account as information was considered too little, with high level of 




2.2 Current model performance. 
 
 
The second part of this research will aim at assessing the potential of increasing 
quality through cost reduction that the creation of a Group Purchasing 
Organization could generate. An analysis of the current purchasing model will be 
undertaken to understand its performance and possible weaknesses. The goal of 
analysing the current purchasing model is to track the evolution of cost 
efficiency since the introduction of centralized purchases and the intervention of 
the SPMS in the buying process with the implementation of framework 
agreements in 2013. Therefore, the performance analysis of the current 
purchasing model will only consider costs and purchases that were directly 
channelled through the SPMS (centralized/aggregated model) or those that were 
performed by the entities of the Portuguese Health System under framework 
agreements (distributed model). It will then be assessed whether the 
implementation of a Group Purchasing Organization would better fit the 
Portuguese Health System in order to increase the quality of the services 














1. Quality indicators 
1.1 Readmission rate. 
 
 
With the objective of assessing quality levels and the evolution quality has 
experienced over the last years in healthcare services providers, data from the 
Portuguese Healthcare Service will be collected on different quality indicators. 
The first indicator to be presented and analysed is the readmission rate in a 
healthcare unit in a period of 30 days. This indicator measures the percentage of 
patients that are readmitted to the hospital within 30 days after their discharge 
from it. Data has been collected on 49 different healthcare units that belong to 
the National Healthcare System covering all the geographies of the country from 
January 2013 until October 2017.  
 
 















Readmission rates between 2013 and 2017
2013 2014 2015 2016 2017
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Looking at the data collected, this quality indicator has been improving for the 
last 4 years except between 2013 and 2014 where it has experienced a very 
small increase. The biggest enhance is reported in the last year of the analysis 
where the indicator decreased by more than 2 percentage points. Even if the 
data about 2017 is not complete (at the time of the study, data for November and 
December is not available), this number is still trustworthy as rates from the 2 
last months of the year are never the highest and are always above the average. 
As this quality indicator has been falling continuously in the last 3 years, it can be 
stated that quality improved during these years in the Portuguese Healthcare 




1.2 Consultations provided in a timely manner. 
 
The maximum response time guaranteed is an indicator developed by the 
Portuguese Health system that assesses the capacity of a health unit providing a 
consultation to a patient in a period of a time that is acceptable according to his 
clinical situation. This indicator depends on multiple aspects of the clinical 
situation of the patient and can range from 7 to 120 consecutive days after the 
patient’s request; this indicator does not cover urgency situations. It is calculated 
by dividing the total number of consultations provided within the maximum 






Figure E: Percentage of consultations provided to patients within the maximum guaranteed time 
between 2013 and 2017. (SNS, 2018) 
 
 
Data about medical appointments was collected in all geographical regions of 
Portugal between January 2013 and October 2017. It was then evaluated 
according to the maximum response time guaranteed with the results shown in 
Figure E. Looking at the data collected, there is no clear trend reported in the 
evolution of this indicator as it increased between 2013 and 2014 and then 
decreased until 2017. The global evolution between the 5 years analysed is 
negative with the indicator dropping from 73,54% to 71,25% in the last year and 
staying above the average of the whole period, 73,27%. The weak performance 
of this indicator can be explained by the evolution of the absolute number of 
medical appointments that experienced a significant growth during the period in 
analysis, as shown in Appendix C. This number rose consecutively between 2013 
and 2017 with more 1.4 million surgeries performed in 2016 than in 2013. This 


















Percentage of consultations provided in a 
timely manner between 2013 and 2017
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1.3 Delay time until surgery. 
 
Continuing the analysis of the quality of services provided in the Portuguese 
Health System, another indicator that can be useful to understand its evolution in 
the last years is the delay time within each surgery is performed. This is the gap 
of time between the first date in which the surgery is scheduled and the date 
where the surgery is actually performed. The smaller the average delay time for 
a surgery is and the better it is for the performance of healthcare unit as more 









Time Until Surgery 
2013 1 329 243 1 305 648 0,98 
2014 1 276 516 1 221 572 0,96 
2015 1 220 021 1 185 360 0,97 
2016 1 137 059 1 044 445 0,92 
2017 490 600 443 614 0,90 
Figure F: Delay time until surgery between January 2013 and October 2017. (SNS, 2018)   
 
Data was collected monthly between January 2013 and October 2017 and covers 
all the geographical areas of Portugal (Figure F). The total number of surgeries 
scheduled have been decreasing every year of the period analysed; this number 
fell 14,4% between 2013 and 2017.  Consequently, the total days of delay also 
decreased during the period. But both have not been decreasing at the same rate. 
If we look at the average number of days of delay until the surgery, it has been 
significantly decreasing every year between 2013 and 2017.  It fell almost 8% 
from 0,98 days to 0,90 days. The evolution of this indicator is very positive and 
even if the total number of surgeries scheduled has considerably decreased 
between 2013 and 2017, the quality level has increased according to the days of 







2. Cost indicators 
2.1 Cost per medicine package 
 
Considering the objective of assessing whether the trend of supply chain costs in 
the Portuguese Health System was increasing or decreasing for the last years, 
data has been collected on different cost indicators. More than understanding if 
costs have been rising or dropping, it is important to understand the evolution of 
cost efficiency. Considering this last statement, the first cost indicator to be 
analysed will be the average cost per medicine package. The scope of the data 
collected is all the medicine packages that were delivered to patients of the 
Portuguese Health System in community pharmacies and public subsystems. The 
data was collected between 2011 and 2018 and covers two different types of 
medicines: 
- In-house use: medicines that are administrated to the patient during his 
stay at the hospital. 
- Generics: medicines that are prescribed to the patient, to be 
administrated after his leave of the hospital.  
 
Year 




Nº of Packages 
(In-house) Total cost (In-house) 
2011 42 420 591,00 487 874 135,71 139 850 812,00 2 124 571 961,50 
2012 49 425 719,00 389 109 333,54 140 017 420,00 1 855 642 761,08 
2013 58 198 520,00 421 054 450,64 149 086 465,00 1 849 703 510,90 
2014 62 474 459,00 452 086 139,01 153 020 413,00 1 873 043 848,45 
2015 64 060 231,00 460 614 902,67 154 964 976,00 1 891 939 587,36 
2016 64 533 900,00 464 549 301,05 155 972 138,00 1 887 107 629,07 
2017 65 549 512,00 471 249 527,66 157 349 422,00 1 913 103 570,76 
Figure G: Total cost of medicine package between 2011 and 2017 for generics and in-house used 
medicines. (SNS, 2018). 
 
The number of packages used has been rising both in generics and in-house used 
medicines since 2011 (Figure G). The total cost of each type of medicine followed 
the same trend during this period despite a few exceptions. Looking further at 
the price per package, shown in figure H, we can see the positive evolution of this 
cost indicator. Notwithstanding some slight increments, the price per package of 







Evolution In-house Package 
Average Price 
Evolution 
2011 11,50  15,19  
2012 7,87 -31,55% 13,25 -12,76% 
2013 7,23 -8,10% 12,41 -6,38% 
2014 7,24 0,02% 12,24 -1,34% 
2015 7,19 -0,64% 12,21 -0,26% 
2016 7,20 0,11% 12,10 -0,90% 
2017 7,19 -0,13% 12,16 0,49% 
Figure H: Average price per medicine package between 2011 and 2017. (SNS, 2018). 
 
 
The global reduction between 2011 and 2017 was of 37% for the generics and 
20% for the in-house used medicines.  This reduction can be explained by the 
evolution of the pharmaceutical drugs industry in what regards to development 
and innovation but also by the increasing costs efficiency of the Portuguese 
Health System. This is achieved with more bargaining power over suppliers, 
boosted by the conclusion of framework agreements (SPMS, 2015). 
 
2.2 Mix of costs incurred by the PHS and by the patient with 
medicines. 
 
After analysing the total amount spent with medicines and the average price per 
package, it is important to decompose the mix of costs incurred between the 
Portuguese Health System and the patient. With this assessment, it can be then 
concluded which stakeholder is taking more advantage of a decrease in the 
overall medicines cost per package and which stakeholder is losing more value 
with an increase. For this analysis, data was collected between 2011 and 2017 
about the total cost incurred by each stakeholder with in-house used medicines 
(Figure I). To assess the evolution of the mix, the total cost was divided by the 
total number of in-house medicine packages consumed each year, retrieved from 





















2011 1 325 999 501,40 9,48  798 572 460,10 5,71  
2012 1 173 075 461,70 8,38 -11,64% 682 567 299,38 4,87 -14,63% 
2013 1 160 219 374,52 7,78 -7,11% 689 484 136,38 4,62 -5,13% 
2014 1 170 352 629,69 7,65 -1,72% 702 691 218,76 4,59 -0,70% 
2015 1 182 180 184,90 7,63 -0,26% 709 776 672,70 4,58 -0,26% 
2016 1 189 820 191,03 7,63 0,00% 697 287 438,04 4,47 -2,39% 
2017 1 213 512 875,71 7,71 1,10% 699 590 695,05 4,45 -0,55% 
Figure I: Mix of costs of in-house medicines between 2011 and 2017 (SNS, 2018) 
 
The evolution of the cost per in-house medicine package incurred by the patient 
fell continuously from 2011 until 2017 with a global decrease of 22% during the 
whole period in analysis; the patient was paying 1,26€ less per package in 2017 
than in 2011. Looking at the side of the Portuguese Health system, the evolution 
is fairly similar except a small increase of the cost in the last year of the period, 
reflecting the increase of the price per package between 2016 and 2017. That is 
why the Portuguese Health System was the part worse off according to the 





Percentage of total 
cost incurred by the 
PHS 
Percentage of total 




2011 62,41% 37,59%  
2012 63,22% 36,78% Patient 
2013 62,72% 37,28% PHS 
2014 62,48% 37,52% PHS 
2015 62,48% 37,52% Neutral 
2016 63,05% 36,95% Patient 
2017 63,43% 36,57% Patient 
Figure J: Percentage of in-house medicines total cost incurred by each stakeholder between 2011 




 The patient was worse off between 2012 and 2014. Between 2014 and 2015, 
there was no part better off as both experienced exactly the same percentage of 
decrease and consequently maintained their share of the total cost. Linking this 
analysis to quality, the consumer of the Portuguese Health System was paying 




3. Current model performance and overview 
3.1 Evolution of framework agreements 
 
Framework agreements aim at selecting companies that fill the needs of the 
institutions of the Portuguese Health System being that it simplifies the 
acquisition process and consequently help reducing the total cost of materials 
purchased. (SNS, 2018). Framework agreements only take effect in the 
distributed model where the healthcare unit undertakes the purchase without 
the intervention of the SPSMS. This indicator was considered in this study due to 
its potential of reducing overall purchasing costs and to reduce the total 
purchasing effort, a common characteristic to a GPO. The first framework 
agreement was concluded in 2014 and since then this number has been 
increasing every year (Figure K).  
 
Year of Conclusion Nº of Agreements Concluded Nº of Suppliers Covered 
2014 1 8 
2015 17 268 
2016 20 309 
2017 24 312 
2018 20 418 
Figure K: Evolution of framework agreements between 2014 and 2018. (SNS, 2018) 
 
The total number of suppliers covered by framework agreements has also been 
rising since its implementation in the buying process. Given that more than 90% 
of the contracts are in force for only 3 years, some of the agreements may 
already have expired if they were not renegotiated or if the agreement was not 
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concluded again. Nevertheless, the evolution of this indicator is quite positive as 
the total number of agreements and suppliers covered has increased since 2014 
and the trend seems to stay positive as in 2018, only until March, 20 agreements 
were celebrated with more than 400 suppliers. With the number of framework 
agreements rising as well as the number of suppliers covered by these, the 
amount of savings is expected to grow accordingly, due to better trading 
conditions and simplified buying processes (SPMS, 2015). 
 
 
3.2 Savings generated by the SPMS on purchases. 
 
Since the beginning of the intervention of the SPMS in the buying process in 
2013, the Portuguese Health System has benefited considerably with the results 
showing big gains in cost efficiency. Since its creation, this entity has seen its 
field of activity increasing exponentially. Indeed, in 2017, the total volume of 
purchases channelled through the SPMS was of 1.308 million euros, which 
represents an increase of 55% against the period of 2016 where this number 
was of 845 million euros (Figure L). Though the growth was not so strong, the 
purchasing activity also increased in 2015 and 2016 at the rates of 7,8% and 
21% respectively. The total amount of purchases undertaken by the SPMS 
doubled between 2014 and 2017. As a consequence, the amount of savings 
generated by the activity of this entity in the buying process of products and 
services for the Portuguese Health System also experienced a considerable 
growth in this period with exception for 2015. The total savings almost doubled 





Figure L: Purchasing activity of the SPMS from 2014 to 2017. (SPMS, 2018)  
 
These savings took place from a wide range of purchases of products and 
services. These purchases are divided by health related expenses such as 
medicines and medical equipment (92% of the total amount), and cross-
sectional expenses such as electricity or facilities maintenance, as shown in 
Appendix D. The cross-sectional expenses are not directly related to health but 
these are costs that need to be incurred to provide care and therefore, they were 
considered in the analysis.  Regarding the nature of savings, 96% were 
transactional savings resulting from the attainment of better purchasing 
conditions created by the SPMS for the entities of the Portuguese Health System, 
which includes framework agreements. The remaining were procedural savings 
related to the reduction of expenses with resources allocated to the execution of 
the procedures and their publication costs. Concerning the source of the savings, 
65% came from the aggregated/centralized model where purchases are directly 
performed by the SPMS and 35% came from the distributed model where the 
entities of the Portuguese Health System make the purchases under framework 
agreements. The 116,9 million euros saved in the aggregated model contrast 
with the 42,5 million euros (33%), reported in 2016. It turns out that an 
inversion of proportions is taking place as the centralized model increased and 
the distributed model decreased in what regards to savings. This turnaround can 
be explained by the activity of the SPMS that is becoming much more 
comprehensive and its role within the Portuguese Health System as an entity 
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V. Conclusion and Future Research 
 
The study undertaken in this dissertation aimed at assessing ways to increase 
the overall quality of services provided by the Portuguese Healthcare System 
primarily with the reduction of supply chain costs. Given that supply chain costs 
are a wide concept, this study focused on supply chain costs efficiency to make 
the analysis of different periods more consistent. An extensive analysis of cost 
and quality indicators was conducted to understand the evolution of these two 
factors and their linkage within the period between 2011 and 2017. The analysis 
was performed with data retrieved from operational, financial and performance 
reports made available by the Portuguese Health System and the SPMS.  
Conclusions were drawn and deductions were made considering all the data 
collected as accurate and trustworthy.  
 
 
1. Evolution of costs. 
 
Considering the data collected about the total cost incurred with medicines 
(Figure G), costs rose consecutively between 2013 and 2017 excluding one small 
exception. The periods where this indicator has increased can be explained by 
two main factors. The activity of healthcare units may have also increased with 
for example more patients treated and more surgeries performed. The other 
factor that can generate higher costs is the loss of cost efficiency (Zelman et al., 
2009). These two phenomena can happen at the same time and the opposite is 
also true: less activity and gains of cost efficiency can generate lower costs. 
Therefore, cost efficiency was the key element to assess the performance of the 
Portuguese Healthcare System in what regards to costs.  The better and more 
consistent indicator for this assessment was the price per package of medicines 
for both generics and in-house. The evolution of both between 2011 and 2017 
was very positive with the price per package falling through the whole period at 
a rate of 37% for generics and 20% for in-house. The price increases during the 
period, besides being very few, were always above 0,5%. Cost efficiency 
increased during this period according to this indicator and to others that were 
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not taken into account for the analysis such as the cost per patient that 
decreased 8% from 27.218€ to 24.943€ (SNS, 2017). 
 
 
2. Evolution of quality. 
 
Data collection about quality was more extensive as there were multiple reports 
focusing on the operational aspect of health and its continuous monitoring. To 
perform the analysis were chosen the ones with more consistent information 
and connection to this issue. These reports reflect the quality of services 
provided in the Portuguese Healthcare System as they measure indicators that 
assess if the population is being better or worse treated through the years. Two 
of the three indicators selected for the analysis experienced very positive 
evolutions for the period between 2013 and 2017: the readmission rate and the 
waiting time for a surgery. Both indicators improved consecutively each year 
between 2015 and 2017. The total number of medical appointments provided 
within the maximum response time guaranteed was the only quality indicator 
that saw its performance weaken during the period. This poor performance was 
mainly caused by the considerable growth of medical appointments between 
2013 and 2016 that rose at an average yearly rate of 7,5%.  
 
3. Relation between costs and quality. 
 
A service provided with high quality does not have necessarily high costs 
associated and high costs does not guarantee good quality of services by itself; 
but there is always need to incur in costs to provide some level of quality. 
Starting with this theory about healthcare costs developed by Donabedian, this 
study focused on establishing a linkage between costs and quality and assessing 
if one has a direct influence in the other. As stated before, costs in the Portuguese 
Healthcare System have been rising consecutively since 2013 but cost efficiency 
has experienced a significant growth during the period between 2011 and 2017. 
The impact of cost efficiency in quality is not pure. Nevertheless, considering that 
the global evolution of two quality indicators between 2013 and 2017 is 
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considerably positive and the third with a negative evolution mainly caused by a 
large growth of the activity, there is a positive relation between cost efficiency 
and quality: positive variations in cost efficiency can generate positive variations 
in quality. Furthermore, the customer of the Portuguese Health System is not 
paying more for the quality of services provided. As shown in Figure H, the total 
cost incurred by the patient with in-house medicines packages dropped 
consecutively between 2011 and 2017. That means that for a certain level of 
quality provided, the patient is not paying more. 
 
4. Evolution of the current purchasing model performance. 
 
An analysis of the current purchasing model considering exclusively the 
transactions that were performed through the procedures set up by the SPMS 
was undertaken. Created in 2010, the SPMS intervenes in the buying process 
since then and since 2013 that its performance and savings have been 
monitored. Through the centralized/aggregated model and the distributed 
model, healthcare units may make use of this entity to purchase products and 
services. The process is as follows in Figure M and always start with the 
healthcare unit need for a product or service and finishes with the purchase. In 
blue arrows are represented the activities where the SPMS has intervention and 
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 The activity of the SPMS grew exponentially between 2014 and 2017 and in the 
latest year, more than 1300 million euros were purchased through the 
distributed model and the centralized/aggregated model. As a consequence, it 
generated savings of 179 million euros in 2017. This was motivated by a more 
comprehensive scope of the activity of the SPMS, that covered the purchases of 
more types of items, and by the substantial growth of framework agreements 
concluded.  The total savings increased significantly since this indicator has been 
monitored and principally between 2015 and 2017 with a growth of 98%; the 
total amount purchased through the SPMS also increased by 87% during this 
period. This means that increasing the amount purchased through the SPMS 
enhances global savings because better conditions are achieved for a bigger 
range of items. 
 
 
5. The opportunity of a GPO implementation in the Portuguese 
Healthcare System. 
 
The operation of the centralized/aggregated model is the closest to a GPO 



















Figure N: Purchasing process for a healthcare unit integrated in a GPO (Burns & 
Lee, 2008) 
 
 An entity, the SPSM in this particular case, negotiates and establish the 
purchasing conditions for a certain range of products and services directly with 
suppliers. The acquisition is then performed centrally for all the institutions that 
compose the Portuguese Healthcare System; the healthcare units have no 
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intervention in the process. The Portuguese Healthcare System benefits from it 
because better buying conditions are achieved due to more bargaining power. 
The suppliers also benefit as they get bigger volume assigned. The major 
difference to a GPO has to deal with the absence of fees that both parties have to 
pay. In the case of the institutions of the Portuguese Healthcare System, the 
membership fee would not be charged because the entity that would manage the 
GPO would be publicly owned by the government. Regarding the contract 
administration fee charged to suppliers, it would be negotiated along with the 
purchasing conditions. Considering the current set up of the SPMS and its 
intervention on the purchases for the Portuguese Health System, it would be 
equivalent to a GPO in the medium to long term if the amount purchased by the 
entity continued to increase over the years until reaching the total volume. For 
this transformation to happen, the distributed model would have to be 
discontinued. The benefits of a GPO in the Portuguese Healthcare System would 
be multiple whether it was created from scratch or through the transformation 
of the SPMS in a GPO. With all the products and services being acquired centrally 
by the same entity, much more savings could be generated as it has already been 
proven by the centralized model of the SPMS. Consequently, costs efficiency 
would be improved and the focus on the operational activities would be 
strengthened which would result in higher quality of healthcare services 
provided. This would all be facilitated by the reduction of information flows that 
this transformation would generate; a GPO model would only have one 
information flow (Figure N) against three that the current model has (Figure M). 
 
 
6. Limitations and future research. 
 
This study was conducted from start to end making use of secondary data, 
already collected and made available by third parties, principally the Portuguese 
Health System and the SPMS. With it comes the first major limitation: 
trustworthiness of data. Given the massive dimension of the Portuguese 
Healthcare System with 99 healthcare units (Pordata, 2017), the probability of 
missing data or wrong data due to human error is very high. Hence the results of 
45 
 
this study could be biased by discrepancies between reality and the reported 
data. Secondly, the indicators chosen to integrate the analysis were sometimes 
the ones that were available and not the ones that were more suitable to the 
study. This affected principally cost indicators where only the cost per package 
of medicines was used to make the analysis due to lack of data available.  
Future research about the subjects developed during this study is endless as 
reducing costs and increasing quality of healthcare services is a challenge that 
will be timeless. Regarding the creation of a Group Purchasing Organization in 
the Portuguese Healthcare System, a rigorous analysis of costs associated with 
its implementation would have to be undertaken. Transforming the SPMS, in 
what regards to purchasing activities, into a GPO is also an hypotheses to be 
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Areas of emphasis between two supply chain operations with progress made since 









Year Total number of consultations 
provided 
Total number of consultations 
provided within the maximum 
response time 
2013 6 125 321,00 4 504 593,00 
2014 6 892 109,00 5 207 556,00 
2015 7 189 711,00 5 335 289,00 
2016 7 578 085,00 5 425 432,00 
2017 5 586 548,00 3 980 198,00 
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